AbbVie Bets Big on Early-Stage Biotech

AbbVie is poised to shell out $10.9 billion for Apogee Therapeutics — a bold, early-stage bet on a company with no approved drugs yet. Focused on antibody therapies for inflammatory diseases, Apogee’s lead candidate, zumilokibart, targets skin inflammation and could be dosed just twice a year — a major leap over current treatments. This move signals AbbVie’s pivot from buying established products to investing in high-potential pipelines, driven by the need to replace fading blockbuster revenue as Humira faces generics. While past bets like Capstan show precedent, this is AbbVie’s biggest acquisition since Allergan — a strategic gamble on future growth. Wall Street is watching closely as big pharma increasingly trades cash for time in the face of patent cliffs. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/4f28123b47aabeed